Always Remember - Buy The Dip

Sentiment Analysis For AAVL

The news is currently generally neutral for AAVL.

Based on TextBlob analysis of Yahoo! Finance news summaries for AAVL on 2015-08-21.

Yahoo! Finance News for AAVL

The Zacks Analyst Blog Highlights: Omeros, AbbVie, Kite Pharma and Avalanche
For Immediate Release Chicago, IL August 20, 2015 Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks

Why Shares of Avalanche Biotechnologies Inc. Jumped Today
What Shares of Avalanche Biotechnologies a clinical stage gene therapy company focused on developing treatments for diseases of the eye, move higher by about 10% today after the stock received an analyst

Avalanche Biotechnologies (AAVL) Q2 Loss Narrows Y/Y
Avalanche Biotechnologies, Inc.AAVL reported second quarter 2015 loss of 38 cents per share, a penny wider than the Zacks Consensus Estimate of a loss of 37 cents but narrower than the year ago loss of $2.27. In the reported

Friday Sector Laggards: Biotechnology, Apparel Stores
In trading on Friday, biotechnology shares were relative laggards, down on the day by about 1.1%. Helping drag down the group were shares of Avalanche Biotechnologies ( AAVL ), down about 24.5% and shares of Kite Pharma ( KITE

Why Avalanche Biotechnologies Shares Tumbled -- Again
What Shares of Avalanche Biotechnologies , a clinical stage gene therapy company focused on developing treatments for diseases of the eye, fell by nearly 15% in after hours trading yesterday. This

ONTX Inspired, Avalanche Triggers Panic Again, NBIX Awaits Data In Q4
ONTX Inspired, Avalanche Triggers Panic Again, NBIX Awaits Data In Q4

These 2 Biotech Stocks Cratered in 2015 -- Is 1 Now a Buy?
Source Cancer Institute of Columbia For the most part, biotech stocks have been having a great 2015. The iShares Nasdaq Biotech Index , for instance, has essentially clobbered the broader markets

Biogen (BIIB) Slips 2.8%, Lead R&D Executive Set to Leave - Analyst Blog
BiogenBIIB announced that its lead research and development (R&D) executive, Douglas Williams, Ph.D., is about to leave the company at the end of July. Williams will leave the position at Biogen to become the CEO of an as yet

Aquinox Shares Nosedive after Lead Candidate Disappoints - Analyst Blog
Aquinox Pharmaceuticals Inc.AQXP was down approximately 67.5% after the company announced that its lead candidate, AQX 1125, disappointed in the phase II FLAGSHIP study. The multicenter, randomized, double blind, placebo controlled FLAGSHIP study evaluated the use of once daily

Epizyme/Celgene Extend Research Deal for HMT Inhibitors - Analyst Blog
Epizyme, Inc.EPZM and Celgene Corporation CELG have amended and restated their agreement and extended the research collaboration agreement at least for three additional years. As per the terms of the deal, Celgene will enjoy the option to license histone

Vanda's Sleep Disorder Drug Hetlioz Gains Approval in EU - Analyst Blog
Vanda Pharmaceuticals Inc.VNDA announced that the European Commission (EC) has approved Hetlioz for the treatment of non 24 hour sleep wake disorder in totally blind adults. We note that the EC has also confirmed orphan drug designation for Hetlioz

Alexion Hypophosphatasia Drug Strensiq Approved in Japan - Analyst Blog
Alexion Pharmaceuticals, Inc.ALXN announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Strensiq for patients suffering from hypophosphatasia. The company expects initial patients with HPP in Japan to start commercial treatment with Strensiq toward the end

Gilead's (GILD) HCV Drug Harvoni Gets Approval in Japan - Analyst Blog
Gilead Sciences, Inc.GILD announced that the Japanese Ministry of Health, Labour and Welfare has approved its hepatitis C virus (HCV) drug Harvoni as a once daily single tablet regimen for the suppression of viremia in patients with genotype 1

Applied Genetic Up on Biogen Deal for Eye Disease Drugs - Analyst Blog
Applied Genetic Technologies CorporationAGTC was up approximately 17% after it announced a collaboration and license agreement with Biogen BIIB for the development of gene based therapies for multiple ophthalmic diseases. The transaction is expected to close in the third

Vertex Pharmaceuticals' CF Drug Orkambi Gets FDA Nod - Analyst Blog
Vertex Pharmaceuticals IncorporatedVRTX received a major boost with the FDA approving its cystic fibrosis (CF) treatment, Orkambi. Orkambi, a combination of lumacaftor and Kalydeco (ivacaftor), an already marketed CF drug in the company's portfolio, is approved for the treatment

Express Scripts Reports Public Exchange Pharmacy Trends - Analyst Blog
Express Scripts Holding CompanyESRX announced data from the Exchange Pulse report, which compared prescription medication usage among exchange plan enrollees to patients enrolled in a traditional health plan between the first quarter of 2014 and the first quarter of

Avalanche Biotechnologies Inc. (AAVL) Is Sinking After Study Results
Avalanche Biotechnologies Inc. (AAVL) Is Sinking After Study Results